Insider Selling: Hims & Hers Health (NYSE:HIMS) Insider Sells 7,054 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Deborah Autor sold 7,054 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $258,952.34. Following the completion of the sale, the insider directly owned 6,175 shares of the company’s stock, valued at $226,684.25. The trade was a 53.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Hims & Hers Health Stock Down 0.7%

HIMS stock traded down $0.23 during trading on Thursday, hitting $34.74. 11,410,870 shares of the company’s stock traded hands, compared to its average volume of 30,867,883. The firm has a market capitalization of $7.91 billion, a P/E ratio of 64.33, a PEG ratio of 7.29 and a beta of 2.41. Hims & Hers Health, Inc. has a 1 year low of $23.97 and a 1 year high of $72.98. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. The business has a fifty day simple moving average of $42.69 and a two-hundred day simple moving average of $48.78.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The company had revenue of $598.98 million for the quarter, compared to analysts’ expectations of $578.99 million. During the same quarter in the prior year, the company earned $0.32 EPS. The firm’s quarterly revenue was up 49.2% on a year-over-year basis. Sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health announced that its Board of Directors has authorized a share repurchase plan on Monday, November 17th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to buy up to 3% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s board of directors believes its shares are undervalued.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. HighTower Advisors LLC acquired a new stake in Hims & Hers Health during the 1st quarter worth about $482,000. Fox Run Management L.L.C. purchased a new position in shares of Hims & Hers Health in the first quarter worth about $287,000. American Century Companies Inc. raised its stake in shares of Hims & Hers Health by 31.5% in the first quarter. American Century Companies Inc. now owns 185,065 shares of the company’s stock worth $5,469,000 after purchasing an additional 44,307 shares during the last quarter. Cresset Asset Management LLC acquired a new stake in shares of Hims & Hers Health during the first quarter worth about $291,000. Finally, Brooklyn Investment Group boosted its position in Hims & Hers Health by 26,242.9% in the first quarter. Brooklyn Investment Group now owns 1,844 shares of the company’s stock valued at $54,000 after buying an additional 1,837 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

HIMS has been the subject of a number of recent research reports. UBS Group set a $32.00 target price on shares of Hims & Hers Health in a report on Tuesday, November 4th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday. BTIG Research reissued a “buy” rating and set a $85.00 target price on shares of Hims & Hers Health in a research report on Tuesday, November 4th. Bank of America raised their target price on shares of Hims & Hers Health from $28.00 to $32.00 and gave the company an “underperform” rating in a research note on Tuesday, November 4th. Finally, Leerink Partnrs raised shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, December 4th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $45.50.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.